# OnCo record tilatamig-samrotecan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tilatamig-samrotecan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tilatamig-samrotecan" ;
  schema:name "Tilatamig samrotecan"@en ;
  schema:description "AstraZeneca's EGFR×c-MET bispecific ADC, the most advanced in the most crowded next-generation ADC target pair."@en ;
  schema:url <https://onco.cc/drugs/tilatamig-samrotecan/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=AZD9592> ;
  onco:status "phase-2" ;
  onco:modality "Bispecific ADC" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-adc/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/met/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct05647122/> .